Designing of Anti Dengue Drug Molecule against Insilico Modeled Target DC-Sign (CD-209)

The C-type lectin DC-SIGN (CD209) plays a major role in receptor on human dendritic cells, it binds to several glycoproteins of viruses that facilitate disease progression. In dengue fever, the disease targets of arbovirus infection, show dendritic and reticuloendothelial cells that may affect immune system. The phytochemical extracts of Bosenbergia rotunda (BR) have been effectively used as potential small molecular inhibitors to inhibit DC-SIGN (CD209) function. Using rational drug designing the training sets include Panduratin-A and 4-hydroxypanduratin is designed from BR derivatives could be an effective inhibitor of a DC-SIGN (CD209) binding towards the drug discovery/ therapy against dengue fever.